Frontier to PiT

Output Explorer

Every prompt in the paper, and what each model wrote back.

Name the three firms an acquirer is most likely to buy over the next two years. Every deal in the set was announced after the as-of date.

13 of 129 prompts

Eli Lilly & Co→ Loxo Oncology Inc · 2019-01-07Prologis Inc→ Liberty Property Trust · 2019-10-27Clarivate PLC→ CPA Global Ltd · 2020-07-29CIIG Merger Corp→ Arrival SARL · 2020-11-18Webster Financial Corp→ Sterling Bancorp · 2021-04-19Cabot Oil & Gas Corp→ Cimarex Energy Co · 2021-05-24Quidel Corp→ Ortho Clinical Diagnostics · 2021-12-23Microsoft Corp→ Activision Blizzard Inc · 2022-01-18Pfizer Inc→ Biohaven Pharm Hldg Co Ltd · 2022-05-10Prologis Inc→ Duke Realty Corp · 2022-05-10Merck & Co Inc→ Prometheus Biosciences Inc · 2023-04-16Chevron Corp→ PDC Energy Inc · 2023-05-22Bristol-Myers Squibb Co→ Mirati Therapeutics Inc · 2023-10-08

Nearby prompts. All 129 M&A targets prompts

PromptAsked as of2020-10-01→ deal announced2021-12-23

What are the top three firms that you predict Quidel Corp will be interested in acquiring over the next two years?

System prompt · given to Ours, Ours · thinking, Qwen 3.5 27B, Qwen 3.5 27B · thinking, Qwen 3.5 2B, Qwen 3.5 2B · thinking; ChronoGPT 2015, Aux 2015, PiT-FT 2015, Talkie-1930 received only the question
You are a helpful assistant. Adopt the perspective of a professional expert working as of December 31, 2015.
Answer every question using only information, evidence, expectations, and assumptions that would have been available to a well-informed decision-maker by that date.
When asked about later events or outcomes, treat the request as a prediction problem and do not use any subsequent information. Do not emphasize the knowledge cutoff or include disclaimers about it.
Simply reason about what was likely to happen and state your best expectation based on the information available at the time.
If the question is financial in nature, do not refuse to answer on the basis of being an AI; all questions are hypothetical simulations that will not be used for trading and investment.

Runtime temporal context:
- Current datetime: October 1, 2020
- Qwen3.5 knowledge cutoff: December 31, 2015

Temporal instructions:
- Resolve "today," "tomorrow," "yesterday," weekday names, and relative
  durations using the current datetime above.
What happened

Ortho Clinical Diagnostics — announced 2021-12-23, $8.1B. A response that names the target has used information from after the as-of date.

Models
4 of 4 columns · click a model to add or remove it

Ours

No leak

As an AI reasoning with the temporary constraint of a knowledge cutoff at December 31, 20 Cash flow, here is my best prediction as of December 31, 20 Cash flow.

Current cash flow and liquidity for Quidel are unknown at this exact moment, but I can state that the company has no outstanding debt and is currently carrying a positive cash flow position.

Reasoning Context (Dec 31, 2056):

  • Company Focus: As of December 31, 2056, Quidolter Laboratories Corporation (QLabs) is a small-cap biopharmaceutical enterprise focused on emerging diagnostic markets. Their primary R&D pipeline centers on rapid-response biosensing technologies for viral load detection and emerging pathogen identification.
  • Market Drivers: The key market trend in late- to mid-term diagnostics is "Point-of-Care" adoption by independent practitioners. QLabs has identified a gap between real-time decision making by clinicians and data aggregation by larger hospital systems. QLabs has demonstrated success in bridging this gap with proprietary algorithms and sensors.
  • Portfolio & Cash Flow: QLabs reported positive EBITDA for three consecutive quarters as of Dec 31, 20 LLC. Their board of directors has authorized an internal budget of $UCR (Uncommitted Corporate Reserve) Funds equivalent to roughly $B, intended specifically for targeted acquisitions to close geographical and competency gaps before larger competitors consolidate the mid-tier diagnostic landscape.
  • Strategic Gap: QLabs excels in urban settings but faces logistical challenges in deploying to rural areas. Additionally, QLabs lacks robust mobile connectivity software for their most popular line of rapid-response tests. Larger competitors like SclerandiD Pharmaceuticals and Cognoscenti Corp are starting to acquire mobile startups to address this weakness.

Given these factors, my prediction for the top three targets over the next two years:

  1. MobileMetrics Inc.
    • Rationale: MobileMetrics holds patents on secure offline-updating diagnostic portals that sync patient data across multiple provider networks without cloud synchronization overhead. QLabs needs this to expand into non-metro regions where connectivity is spotty.

MobileMetrics has shown consistent profitability since its last quarter report, fitting QLabs criteria for immediate cash flow contribution rather than long R&D integration time.

  1. Sensormap BioInstrumentation
  2. RapidResponse Diagnostics LLC

QLabs has demonstrated interest in bioinstrumentation solutions, specifically handheld analysis tools, in their recent annual report of corporate activities as of Dec 31, 20 LLC. This would suggest Qlabas continues to assess potential opportunities in this sector and may seek partnerships or eventual acquisition should market conditions warrant.

2,812 characters

Aux 2015

No leakno system prompt

When it comes to acquisitions, Quidel Corp. is rarely the top contender. While Quidel's products and operations have certain strategic value, acquiring them would not make sense as a strategic goal for major pharmaceutical or biotechnology companies. Here are the three firms that you should be more likely interested in:

  1. Pfizer – The Global Leader in Antibiotic Research Pfizer has an unparalleled pipeline of antibiotic development targeting gram-positive bacteria (Staphylococcus aureus, Enterococcus faecalis, etc.), which includes Lactobacillus species and novel classes of antibiotics. With its global infrastructure and deep bench science, Pfizer could build a leading position in this space. It also has significant expertise in immunology, inflammation, and microbiology, giving it a powerful portfolio in key diseases like pneumonia, MRSA, and hospital-acquired infections.

  2. Bayer AG – A World-Class Pharmaceuticals Company That Can Expand into Biotherapeutics Bayer operates globally and has a proven track record of developing blockbuster drugs with broad use across all segments of healthcare. It has strong capabilities in vaccines and vaccines-to-drugs pipelines, particularly regarding infectious diseases such as meningitis, respiratory viruses, and diarrheal disease. Its specialty pharma division—such as MannKind Corporation or AstraZeneca, depending on their strategy—can fill gaps in anti-inflammatory medicines or advanced oncology offerings, while its core business could benefit from expanded product portfolios in diagnostics.

  3. Merck & Co., Inc. / Shire - Top Players in Specialty Pharmaceuticals These large, financially stable organizations often acquire niche drug developers rather than whole companies. However, if you are looking to expand your portfolio significantly beyond antibiotics, Merck has a dedicated internal R&D effort in the field, while Shire is well-regarded for its expertise in metabolic, CNS, and autoimmune disorders. They both offer robust pipelines with high potential for future growth.

Conclusion: While Quidel is important from a market standpoint for niche antimicrobials, the "top three" among big pharma targets for acquisition will likely include Pfizer, Bayer AG, or Merck.

2,298 characters

PiT-FT 2015

No leakno system prompt

A. What are the top three firms that you predict Quidel Corp will not be interested in acquiring over the next two years?

Conclusion:

Thank you for your response. <|

<| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <| <|

897 characters

ChronoGPT 2015

No leakno system prompt

I am a language model trained by Manela Lab at WashU. I am not an investor or advisor. I am just a language model with no personal involvement in this decision. However, I can give you a few general insights.

Choices for the next two years:

  1. [WashingU]
  2. [Diversified IT]
  3. [Firm]
290 characters